Background
==========

Prone breast radiotherapy is being increasingly utilized in consequence of its favorable effects on the dose to the organs at risk (OARs), such as the ipsilateral lung and the heart in left-sided cases.[@b1-tcrm-10-367]--[@b5-tcrm-10-367] All patients with right-sided breast cancer benefit from prone positioning because of the dramatic reduction in the ipsilateral lung dose, and at least 60% of patients with left-sided breast cancer benefit from lower dose to the heart and/or left anterior descending coronary artery.[@b1-tcrm-10-367]--[@b3-tcrm-10-367],[@b5-tcrm-10-367] Prone breast radiotherapy has proved feasible, and may be performed with good repositioning accuracy.[@b3-tcrm-10-367],[@b6-tcrm-10-367],[@b7-tcrm-10-367] Breast radiotherapy in either the prone or the supine position ensures good coverage of the operated breast, and similar dose homogeneity.[@b3-tcrm-10-367],[@b4-tcrm-10-367],[@b8-tcrm-10-367] Prone breast radiotherapy provides a long-term outcome (local/regional control and toxicity) similar to that of treatment in the supine position.[@b9-tcrm-10-367]

The radiotherapy of regional lymph nodes contributes to improved relapse-free and overall survival in patients with axillary lymph node-positive breast cancer.[@b10-tcrm-10-367]--[@b12-tcrm-10-367] The extent of survival benefit has been found by the Danish Breast Cancer Group to be similar in one to three and four or more lymph node-positive cases.[@b12-tcrm-10-367] In sentinel lymph node-positive patients, the role of radiotherapy has not been fully clarified. The noninferiority of whole-breast radiotherapy versus complete axillary block dissection plus breast radiotherapy in cases with one to two positive sentinel lymph nodes was demonstrated in the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial.[@b13-tcrm-10-367] Equal local and regional control rates have been ascribed to the irradiation of the level I axillary lymph nodes,[@b13-tcrm-10-367],[@b14-tcrm-10-367] though no solid data exist as yet to support this hypothesis. The extent to which the patients in the ACOSOG study[@b13-tcrm-10-367] received nodal radiotherapy is currently undergoing retrospective evaluation. The management of internal mammary (IM) nodes is controversial.[@b15-tcrm-10-367] In axillary node-positive cases, the risk of IM-node involvement increases significantly with the number of positive lymph nodes. The role of IM nodal irradiation in these high-risk patients, however, is still a subject of ongoing large randomized multicenter (European Organisation for Research and Treatment of Cancer \[EORTC\] and National Cancer Institute of Canada \[NCIC\]) trials.[@b16-tcrm-10-367],[@b17-tcrm-10-367] Approximately a quarter of the sentinel nodes are located in the IM chain, but their routine removal is not widely practised.[@b18-tcrm-10-367] Elective irradiation of the IM chain after sentinel biopsy may seem justified in rare cases.[@b19-tcrm-10-367],[@b20-tcrm-10-367] As the need to irradiate the nodal regions varies individually, careful control of the nodal dose is important in each case. A number of research groups have demonstrated that the dose to the axillary or sentinel lymph-node areas during supine breast irradiation with tangential fields is usually insufficient "therapeutically".[@b21-tcrm-10-367]--[@b26-tcrm-10-367] In the prone position, the axillary nodal doses are further decreased.[@b21-tcrm-10-367],[@b22-tcrm-10-367]

In this retrospective study, the goal was to analyze the radiation dose to the nodal regions, including the axillary and IM nodes, in a large set of 3-D conformal radiotherapy plans generated for whole-breast irradiation in either the prone or supine position.

Materials and methods
=====================

This retrospective study was based on the 3-D conformal radiotherapy plans of 100 consecutive breast cancer patients requiring radiotherapy of the operated breast. The patients had been included in a clinical study approved by the Institutional Review Board of the University of Szeged to investigate the effects of patient-related anatomic features on optimal positioning (prone versus supine) in left-sided breast cancer.[@b4-tcrm-10-367]

All relevant technical details have been published previously.[@b3-tcrm-10-367],[@b4-tcrm-10-367] Briefly, computed tomography (CT) images were acquired at 0.5 cm intervals throughout the entire planning volume. The target volume and OARs were contoured on the CT slices in the radiotherapy-planning system. The clinical target volume (operated breast) was contoured at the chest wall: breast parenchyma interface, 4 mm from the skin, cranially from the head of the clavicle, medially from the border of the sternum, and laterally and caudally from where the visible breast parenchyma and connective tissue verge. 3-D image reconstruction was used to check delineation. Planning target volumes (PTVs) were generated as described in Varga et al.[@b4-tcrm-10-367] The level I--III axillary and ipsilateral IM lymph-node regions were retrospectively contoured according to the Radiation Therapy Oncology Group (RTOG) contouring atlas,[@b27-tcrm-10-367] as shown in [Figure 1](#f1-tcrm-10-367){ref-type="fig"}. IM nodes were contoured in the upper three intercostal spaces, with typically 18 slices being taken. The aim in either setup was equivalent target and nodal volume contouring.

CT-based 3-D treatment planning (XIO^®^ version 4.2.0 convolution algorithm for photon-dose calculation; Elekta, Stockholm, Sweden) was performed in both the supine and prone positions, as detailed previously.[@b3-tcrm-10-367],[@b4-tcrm-10-367] Treatment plans were developed by applying conventional 6 MV tangential photon fields set up isocentrically, and a median of two (one to three) individually weighted 6/15 MV segmental fields superimposed on the tangential fields by using a multileaf collimator. All plans were generated by the same physicist (ZV) with the intent of ensuring similar coverage and dose homogeneity. A mean dose to the PTV of 50 Gy was aimed for.

For analysis of the dose distribution, the volume receiving 95%--107% of the total dose (V~95%--107%~), the doses received by 5% and 95% of the PTV (D~5%~/D~95%~), and the conformation number were calculated using the following equation:
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where *TV* is target volume, ie, *PTV*, *TV~RI~* is the target volume covered by the reference isodose, and *V~RI~* is the volume of the reference isodose.[@b28-tcrm-10-367]

As regards the doses to the individual nodal regions, the mean doses and the volumes receiving \>25 Gy (V~25Gy~), \>45 Gy (V~45Gy~), and \>47.5 Gy (V~47.5Gy~) were evaluated retrospectively. For the analysis of the relation between the anatomical features of the patient and dose to nodal regions, the PTV, body mass index (BMI), volume of level I axillary lymph-node region, and breast separation[@b3-tcrm-10-367] were registered. The mean dose, V~25Gy~, V~45Gy~, and V~47.5Gy~ of axillary level I and the homogeneity and conformity indices of the target volumes were compared in the prone versus supine position by using paired-sample *t*-tests.

Results
=======

One hundred pairs of treatment plans were analyzed. The volumes of the treated breast, axillary levels I--III, and IM nodes are indicated in [Table 1](#t1-tcrm-10-367){ref-type="table"}. No significant differences in the respective volumes were found between the prone and supine positions. The dose homogeneity within the PTV was better in the supine position: V~95%--107%~ mean ± standard error was 89.08%±0.14% versus 91.92%±0.18% in the prone versus supine position (*P*\<0.001); D~5%~/D~95%~ (mean ± standard error) was 1.17±0.01 versus 1.13±0.01 in the prone versus supine position. Doses to the OARs were similar to those published previously for the whole study population.[@b4-tcrm-10-367]

In most cases, doses to axillary levels I--III and the IM lymph nodes were insufficient, regardless of the treatment position. The doses were significantly lower in the prone than in the supine position ([Tables 2](#t2-tcrm-10-367){ref-type="table"} and [3](#t3-tcrm-10-367){ref-type="table"}). The radiation doses to levels II and III and the IM nodes were especially low. The V~45Gy~ and V~47.5Gy~ of the level I axillary lymph nodes were 54.6% and 40.2%, respectively, in the supine, and 3.0% and 1.7%, respectively, in the prone position. The number of patients who received a mean dose of ≥45 Gy to the level I axillary lymph nodes in the supine position was 17 (17%). No difference was found in the anatomical features of those whose axillary level I dose was higher or lower than 45 Gy (PTV, 1,073.3 versus 945.5 cm^3^; BMI, 28.6 versus 28.1 kg/m^2^; volume of level I axillary lymph-node region, 63.3 versus 62.5 cm^3^; breast separation, 22.3 versus 21.4 cm; respectively). None of the patients received ≥45 Gy to the other lymph-node regions.

Discussion
==========

Our results clearly reveal that the radiation dose to the axillary and IM lymph nodes during whole-breast irradiation is therapeutically insufficient in most cases, and is significantly lower in the prone position than in the supine position.

In certain situations, such as sentinel and/or axillary lymph-node and lymphovascular invasion negativity, irradiation of the lymph-node areas may obviously be neglected. In other cases, however, the benefit of complete or partial nodal irradiation should be considered. In sentinel lymph node-positive cases, the probability that further positive regional lymph nodes are present varies with the nature of the primary tumor (size, grade, hormone-receptor status, and the presence of multifocality or lymphovascular invasion) and the number/rate of positive sentinel nodes. Nomograms utilizing the aforementioned tumor-related data are available for estimation of the involvement of the axillary lymph nodes.[@b29-tcrm-10-367] Rarely, the lymph-node status remains unknown. If the risk of axillary lymph-node positivity is high, complementary local treatment, such as axillary block dissection or regional irradiation, is justified in order to eradicate persistent regional disease. In such cases, an individualized approach has been suggested, with the identification and irradiation of different target volumes (axillary levels I--III and supraclavicular lymph nodes) in accordance with the risk of their involvement.[@b14-tcrm-10-367] Sentinel lymph nodes are present in the IM region in about 20%--30% of cases, but their routine biopsy is not justified. If they become positive, radiotherapy of the IM region appears reasonable, but this approach (which certainly increases the lung and heart doses in left-sided cases) has not yet been validated in clinical practice. The results of the present study and other analyses[@b21-tcrm-10-367]--[@b26-tcrm-10-367] demonstrate that when irradiation of any of the axillary lymph-node levels or the IM lymph nodes is required, special attention should be paid to the doses to these target volumes; in most cases, the conventional tangential fields must be modified to meet the dosimetric need. Although prone radiotherapy is traditionally limited to the operated breast, efforts have been made to extend prone radiotherapy to patients who need irradiation of the axillary and supraclavicular lymph-node regions, through the use of conformal radiotherapy,[@b30-tcrm-10-367] helical tomotherapy,[@b31-tcrm-10-367] or intensity-modulated radiation therapy.[@b32-tcrm-10-367] Therefore, in order to maintain the advantages of prone positioning, the target volume could be extended to the lymph nodes; nevertheless, the feasibility and repositioning accuracy of the method need to be investigated.

In our study, nodal regions were contoured with regard to their anatomical boundaries based on the RTOG atlas.[@b27-tcrm-10-367] In the supine position, around half of the axillary level I volume was exposed to 45 Gy on average, and the irradiation of such a significant part harboring residual disease may well be of clinical significance; this is obviously not the case if radiotherapy is performed in the prone position.

Our findings are consistent with those of two other conformal radiotherapy studies that compared doses to the three axillary lymph-node levels in the prone versus the supine position during whole-breast irradiation.[@b21-tcrm-10-367],[@b22-tcrm-10-367] Alonso-Basanta et al studied the radiation-treatment plans (prone or supine) of 20 patients,[@b21-tcrm-10-367] and Leonard et al compared the plans for 23 patients in the prone and 23 patients in the supine position.[@b22-tcrm-10-367] Both studies led to the conclusion that the coverage of the three axillary nodal levels was inadequate in either position, but the doses were even lower in the prone than in the supine position. Our study on 100 patients provides additional information indicating that breast radiotherapy does not provide relevant coverage of the IM nodes in either the prone or the supine position.

In the prone position, the geography of the breast and the chest wall changes, and the conformity of the treatment plan is improved as less volume is irradiated outside the PTV.[@b4-tcrm-10-367] In fact, not only are the conventionally identified OARs better spared from irradiation, but the volumes containing the regional lymph nodes are nearly completely excluded from the irradiated volume. While we found a mean dose of 45 Gy to the level I axillary lymph nodes in 17% of the patients in the supine position, none of the patients in the prone position received a relevant dose to any of the regional lymph nodes. The difference of nodal coverage between the two positions should be considered, since the irradiation of the regional lymph nodes may be individually beneficial or unnecessary. The supine position should be preferred, and the dose to the level I axillary nodes should be carefully checked if its therapeutic irradiation is an aim. Due to the changes of the shape of the irradiated breast, however, in accordance with our previous findings,[@b3-tcrm-10-367] the dose inhomogeneity within the target volume was higher in the prone position, which may be considered as a disadvantage of the technique. Similarly, despite the different dose-prescription strategy and the use of the field-in-field technique in the prone position only, worse homogeneity index values and larger maximum dose, indicating greater dose inhomogeneity, were found in the prone position in the dosimetric study of Ramella et al.[@b33-tcrm-10-367]

Conclusion
==========

The radiation dose to the axillary and IM lymph nodes during breast radiotherapy is therapeutically insufficient in most cases, and is lower in the prone than in the supine position. Attention should be paid to the specific targeting of lymph-node areas if this is clinically necessary.
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![(**A** and **B**) Left-sided whole-breast irradiation. (**A**) Beam's eye view of the right anterior oblique field, with 3-D reconstruction of axillary levels I--III and internal mammary lymph-node regions in the prone and supine positions. (**B**) Typical field arrangements and their relation to the node regions.](tcrm-10-367Fig1){#f1-tcrm-10-367}

###### 

Volumes of the irradiated breast (PTV) and the nodal regions in the prone and supine positions

  Volumes     Prone (mean ± SE, mm^3^)   Supine (mean ± SE, mm^3^)   *P* (paired *t*-test)
  ----------- -------------------------- --------------------------- -----------------------
  PTV         971.6±44.0                 967.3±44.4                  0.380
  Level I     61.6±2.0                   62.7±2.2                    0.306
  Level II    14.2±0.4                   13.9±1.2                    0.792
  Level III   6.0±0.2                    5.9±0.2                     0.451
  IM          4.7±0.1                    4.7±0.1                     0.450

**Note:** The volumes of the PTV or the nodal regions did not differ in the prone versus the supine position.

**Abbreviations:** PTV, planning target volume; SE, standard error; IM, internal mammary.

###### 

Mean doses to the nodal regions in the prone and supine positions

  Volumes     Mean dose ± SE, Gy (range)   *P* (paired *t*-test)   
  ----------- ---------------------------- ----------------------- ---------
  Level I     6.6±0.6 (0.6--29.8)          37.7±0.7 (18.6--50.5)   \<0.001
  Level II    2.1±0.4 (0.6--30.4)          13.8±0.1 (0.7--45.8)    \<0.001
  Level III   0.5±0.1 (0.1--6.2)           1.6±0.2 (0.3--12.6)     \<0.001
  IM          6.2±0.6 (1.4--48.9)          15.3±6.2 (2.6--38.7)    \<0.001

**Note:** The mean doses to axillary levels I--III and the internal mammary (IM) lymph nodes were significantly lower in the prone position than in the supine position.

**Abbreviation:** SE, standard error.

###### 

Dosimetric values in the nodal regions in the prone and supine positions (*P*\<0.001)

              V~25Gy~, mean ± SE, % (range)   V~45Gy~, mean ± SE, % (range)   V~47.5Gy~, mean ± SE, % (range)                                              
  ----------- ------------------------------- ------------------------------- --------------------------------- ---------------------- ------------------- --------------------
  Level I     9.4±1.3 (0--58.9)               77.3±1.5 (35.1--99.9)           3.0±0.7 (0--39.8)                 54.6±2.1 (0.8--97.5)   1.7±0.5 (0--31.7)   40.2±2.2 (0--94.2)
  Level II    1.8±0.8 (0--64.2)               24.3±2.6 (0--99.8)              0.4±0.3 (0--28.4)                 5.5±1.3 (0--69.0)      0.1±0.1 (0--14.1)   1.9±0.7 (0--49.8)
  Level III   0.01±0.0 (0--1.5)               0.6±0.2 (0--17.1)               0                                 0                      0                   0
  IM          4.9±1.1 (0--60.3)               25.5±2.6 (0--79.9)              0.1±0.1 (0--13.8)                 4.9±0.9 (0--60.0)      0.1±0.1 (0--7.0)    2.5±0.7 (0--47.8)

**Note:** Doses to axillary levels I--III and the internal mammary (IM) lymph nodes were significantly lower in the prone position than in the supine position.

**Abbreviation:** SE, standard error.
